Breast Cancer Epidemiology Forecast

$ 8.690,00

Breast Cancer Epidemiology Forecast

The breast cancer is currently the most common cancer in females, and it is the second leading cause of cancer death in women (the first is lung cancer), this disease is classified as ICD-9-CM category 174. In the G7 mature markets, Hoffmann-Krueger epidemiologists expect the incident cases of breast cancer to increase from 456 216 cases in 2012 to 460 222 cases in 2022.

  • Countries concerned :

Add to my wishlist

Scope

G7 Mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK)

10-year patient population forecast + 5 years of historical data

 

Key Users

Oncology Market Research - New Product Planning - Business Development & Licensing

Oncology Market Access – Oncology Marketing leaders

 

Insight

Insight into the breast cancer strategy and business development activities

Transparent forecasts methodology and assumptions

Concise and comparable analysis

Key epidemiology assumptions are included to give accurate sizing of patient population, epidemiology forecast, key drivers of patient shares.The oncology drug market is one of the fastest-growing markets in the pharmaceutical industry. The treatment of cancer has shifted away from mass market blockbuster drugs toward a more focused attack on the disease with targeted therapies.

 

Reasons To Buy

Hoffmann-Krueger ECF (Epidemiology Cancer Forecast) rich data set and easy-to-use tool allow you to focus on cancer subpopulation segment of interest. Hoffmann-Krueger  ECF (Epidemiology Cancer Forecast) giving the opportunity to use epidemiological projections of key oncology patient population.

  • Country : Germany | United States | Spain | Italy | France | United Kingdom | Japan
  • Cancer Type : Breast cancer
  • File : xls